LE WE PMID CA
Skin (Neoplasia Melanoma)1741Haut (Neubildung Melanom)

Aneuploidity

Angiogenesis

Anus (Neoplasm)

Apaf1

Arginine

Atypical mole syndrome

Autotaxin ATX

Bortezomib ttProteasom

BRAF

CD152 CTLA4

CD95 FAS Apo1

CD95L FASL

CNS (Metastasis)

CNS (Neoplasia Glioma)

CNS (Neoplasia Neuroblastoma)

CTLA4

EMD273063 ttGD2 ttIL2

Endothelin

Erlotinib ttEGFR

FLT1

Galectin1

Gangliosides

Heparin LMW

IMP3

Interferon alpha (Therapeutic use)

Interferon beta

Interleukin24 MDA7

Ion channel (TRP Family)

Ipilimumab ttCTLA4

KDR

Lymph node (Metastasis and sentinel)

Lysophosphatidate

Melanocyte

Melanoma associated retinopathy syndrome

Melanosom

Methionine deprivation induced stress

Mezerein ttPKC

Neoplasia (Carcinogenesis)

Neoplasia (Dormancy)

Neoplasia (Invasion and metastasis)

Neoplasia (Paraneoplastic syndromes)

Neoplasia (Tumor biology and immunology)

NRAS

NRP1

NUAK2

PLX4032

Prostate (Neoplasia)

Skin (Neoplasia Melanocytoma)

Skin (Neoplasia Melanoma)

SOX10

SOX18

SOX5

SOX9

Stem cell (Neoplasia)

Temozolomide

TRAIL APO2

Tremelimumab ttCLTA4

TRPM1

TRPM8

TRPV6

Wnt beta Catenin TCF

2009  
1
Cutaneous melanoma--atypical variants and presentations.
[19575065] Aust Fam Physician 38(7): 476-82 (2009)
2008  
2
1973  
3
Studies of humoral and cell-mediated immunity in human melanoma.
[4130586] Yale J Biol Med 46(5): 681-92 (1973)
2001  
4
Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases.
[11725182] J Neuroophthalmol 21(3): 173-87 (2001)
2010  
5
Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review.
[21042541] Core Evid 5(-): 39-48 (2010)
2006  
6
Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas.
[17178980] Arch Dermatol 142(12): 1551-8 (2006)
2002  
7
Prevalence of melanoma clinically resembling seborrheic keratosis: analysis of 9204 cases.
[12472343] Arch Dermatol 138(12): 1562-6 (2002)
2010  
8
From melanocyte to metastatic malignant melanoma.
[20936153] Dermatol Res Pract 2010(-): - (2010)
2008  
9
Immunotherapy for advanced melanoma.
[18927541] J Invest Dermatol 128(11): 2596-605 (2008)
2008  
10
Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside.
[18927540] J Invest Dermatol 128(11): 2575-95 (2008)
2008  
11
From UVs to metastases: modeling melanoma initiation and progression in the mouse.
[18787547] J Invest Dermatol 128(10): 2381-91 (2008)
2008  
12
Melanoma, nevogenesis, and stem cell biology.
[18787546] J Invest Dermatol 128(10): 2365-80 (2008)
2007  
13
Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma.
[17159915] J Invest Dermatol 127(4): 900-5 (2007)
2002  
14
Pathways to melanoma development: lessons from the mouse.
[12406321] J Invest Dermatol 119(4): 783-92 (2002)
2002  
15
The role of chemokines in melanoma tumor growth and metastasis.
[12060384] J Invest Dermatol 118(6): 915-22 (2002)
2007  
16
Hedgehog signaling in the murine melanoma microenvironment.
[17762973] Angiogenesis 10(4): 259-67 (2007)
2005  
17
Inhibition of B16 melanoma growth in vivo by retroviral vector-mediated human ribonuclease inhibitor.
[16132620] Angiogenesis 8(1): 73-81 (2005)
2003  
18
Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma.
[15166498] Angiogenesis 6(4): 295-301 (2003)
2002  
19
The dark side of lysosome-related organelles: specialization of the endocytic pathway for melanosome biogenesis.
[11929605] Traffic 3(4): 237-48 (2002)
2009  
20
Molecular markers of tumor progression in melanoma.
[19949544] Curr Genomics 10(4): 231-9 (2009)
2002  
21
Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision.
[12361412] Arch Surg 137(10): 1101-5 (2002)
1997  
22
Advances in the care of the patient with malignant melanoma.
[8998116] Ann Surg 225(1): 15-6 (1997)
1997  
23
Recent advances in the care of the patient with malignant melanoma.
[8998115] Ann Surg 225(1): 1-14 (1997)
1991  
24
Surgical prophylaxis of malignant melanoma.
[2009012] Ann Surg 213(4): 308-14 (1991)
1977  
25
Current management of melanoma.
[327949] Ann Surg 186(1): 1-12 (1977)
2010  
26
Advanced malignant melanoma: immunologic and multimodal therapeutic strategies.
[20224761] J Oncol 2010(-): 689893 (2010)
2007  
27
Medical treatment of uveal melanoma.
[17679486] Tumori 93(3): suppl 27-30 (2007)
2009  
28
2009  
29
Immunotherapy of distant metastatic disease.
[19617297] Ann Oncol 20 Suppl 6(-): vi41-50 (2009)
2009  
30
Small molecules and targeted therapies in distant metastatic disease.
[19617296] Ann Oncol 20 Suppl 6(-): vi35-40 (2009)
2009  
31
Utility of adjuvant systemic therapy in melanoma.
[19617295] Ann Oncol 20 Suppl 6(-): vi30-4 (2009)
2009  
32
Surgery and radiotherapy in the treatment of cutaneous melanoma.
[19617294] Ann Oncol 20 Suppl 6(-): vi22-9 (2009)
2009  
33
2008  
34
Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[18456782] Ann Oncol 19 Suppl 2(-): ii86-8 (2008)
2000  
35
Malignant melanoma: prevention, early detection, and treatment in the 21st century.
[10986965] CA Cancer J Clin 50(4): 215-36; quiz 237-40 (2000)
1996  
36
Surgical management of primary cutaneous melanoma.
[8673694] CA Cancer J Clin 46(4): 217-24 (1996)
1979  
37
2008  
38
State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer.
[18798543] Cancer 113(7 Suppl): 1728-43 (2008)
2008  
39
Adjuvant radiotherapy for cutaneous melanoma.
[18260153] Cancer 112(6): 1189-96 (2008)
2007  
40
Influence of age on survival in childhood spitzoid melanomas.
[17326059] Cancer 109(8): 1579-83 (2007)
2007  
41
Chemotherapy for metastatic melanoma: time for a change?
[17200963] Cancer 109(3): 455-64 (2007)
2006  
42
Molecularly targeted therapy for melanoma: current reality and future options.
[17039502] Cancer 107(10): 2317-27 (2006)
2006  
43
Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma.
[16511841] Cancer 106(7): 1431-42 (2006)
2005  
44
Wide excision without radiation for desmoplastic melanoma.
[16080180] Cancer 104(7): 1462-7 (2005)
2000  
45
Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
[10649252] Cancer 88(3): 589-95 (2000)
1997  
46
Ultra-late recurrence (15 years or longer) of cutaneous melanoma.
[9191524] Cancer 79(12): 2361-70 (1997)
2009  
47
Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma.
[19556964] Cancer Control 16(3): 240-7 (2009)
2009  
48
Sentinel lymph node biopsy for melanoma: indications and rationale.
[19556963] Cancer Control 16(3): 234-9 (2009)
2009  
49
2009  
50
2009  
51
2008  
52
Treatment options for limited or symptomatic metastatic melanoma.
[18596676] Cancer Control 15(3): 239-47 (2008)
2008  
53
Radiation therapy as primary and adjuvant treatment for local and regional melanoma.
[18596675] Cancer Control 15(3): 233-8 (2008)
2008  
54
Therapy for unresectable recurrent and in-transit extremity melanoma.
[18596674] Cancer Control 15(3): 225-32 (2008)
2008  
55
Surgical management of melanoma in situ on chronically sun-damaged skin.
[18596673] Cancer Control 15(3): 216-24 (2008)
2008  
56
The impact of genomics in understanding human melanoma progression and metastasis.
[18596672] Cancer Control 15(3): 202-15 (2008)
2005  
57
Choices in adjuvant therapy of melanoma.
[16258495] Cancer Control 12(4): 236-41 (2005)
2005  
58
Sentinel node biopsy for thin melanomas: which patients should be considered?
[16258494] Cancer Control 12(4): 230-5 (2005)
2005  
59
Cutaneous melanoma: prognostic factors.
[16258493] Cancer Control 12(4): 223-9 (2005)
2004  
60
Malignant melanoma of the conjunctiva.
[15377990] Cancer Control 11(5): 310-6 (2004)
2004  
61
Choroidal melanoma: natural history and management options.
[15377988] Cancer Control 11(5): 296-303 (2004)
2002  
62
The new melanoma staging system.
[11907461] Cancer Control 9(1): 9-15 (2002)
2006  
63
2009  
64
Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.
[19318635] J Natl Cancer Inst 101(7): 452-74 (2009)
2008  
65
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
[19001147] Oncologist 13 Suppl 4(-): 16-25 (2008)
2008  
66
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).
[19001146] Oncologist 13 Suppl 4(-): 10-5 (2008)
2007  
67
Temozolomide for the treatment of metastatic melanoma: a systematic review.
[17914081] Oncologist 12(9): 1114-23 (2007)
2004  
68
Recent advances in melanoma biology.
[15047922] Oncologist 9(2): 182-7 (2004)
2000  
69
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
[10794805] Oncologist 5(2): 144-51 (2000)
2009  
70
Melanoma: molecular pathogenesis and emerging target therapies (Review).
[19424565] Int J Oncol 34(6): 1481-9 (2009)
2006  
71
Malignant melanoma: genetics and therapeutics in the genomic era.
[16912270] Genes Dev 20(16): 2149-82 (2006)
1980  
72
On the histological diagnosis and prognosis of malignant melanoma.
[6988460] J Clin Pathol 33(2): 101-24 (1980)
2004  
73
Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria.
[15585738] JAMA 292(22): 2771-6 (2004)
2006  
74
2006  
75
Unusual variants of malignant melanoma.
[16446716] Mod Pathol 19 Suppl 2(-): S41-70 (2006)
2007  
76
The role of interval nodes in sentinel lymph node mapping and dissection for melanoma patients.
[17873127] J Nucl Med 48(10): 1607-13 (2007)
2006  
77
Role of nuclear medicine in the management of cutaneous malignant melanoma.
[16741305] J Nucl Med 47(6): 957-67 (2006)
2006  
78
Sentinel lymph node biopsy in melanoma.
[16455622] J Nucl Med 47(2): 191-5 (2006)
2003  
79
Patterns of lymphatic drainage from the skin in patients with melanoma.
[12679402] J Nucl Med 44(4): 570-82 (2003)
2002  
80
Procedure guideline for lymphoscintigraphy and the use of intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness 1.0.
[12368382] J Nucl Med 43(10): 1414-8 (2002)
2002  
81
Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma.
[12050328] J Nucl Med 43(6): 811-27 (2002)
1997  
82
Long-term follow-up after uveal melanoma charged particle therapy.
[9440169] Trans Am Ophthalmol Soc 95(-): 171-87; discussion 187-91 (1997)
1995  
83
Risk factors for growth and metastasis of small choroidal melanocytic lesions.
[8719682] Trans Am Ophthalmol Soc 93(-): 259-75; discussion 275-9 (1995)
1984  
84
The ultrastructure of conjunctival melanocytic tumors.
[6398936] Trans Am Ophthalmol Soc 82(-): 599-752 (1984)
1980  
85
Conjunctival melanomas: prognostic factors a review and an analysis of a series.
[7257067] Trans Am Ophthalmol Soc 78(-): 467-502 (1980)
2009  
86
Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland.
[19668544] Clin Ophthalmol 3(-): 49-55 (2009)
2007  
87
High-frequency ultrasound characteristics of 24 iris and iridociliary melanomas: before and after plaque brachytherapy.
[17698751] Arch Ophthalmol 125(8): 1051-8 (2007)
2001  
88
Transpupillary thermotherapy as an adjunct to ruthenium plaque radiotherapy for choroidal melanoma.
[11167280] Acta Ophthalmol Scand 79(1): 19-22 (2001)
1999  
89
Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A meta-analysis of studies including 1,066 patients.
[10463412] Acta Ophthalmol Scand 77(4): 414-7 (1999)
2002  
90
[Choroidal melanoma: current therapeutic approaches].
[11941244] J Fr Ophtalmol 25(2): 203-11 (2002)
1998  
91
From the outside in, or the inside out. Resecting uveal melanomas.
[9602612] Br J Ophthalmol 82(3): 209 (1998)
1997  
92
Retinoinvasive malignant melanoma of the uvea.
[9349160] Br J Ophthalmol 81(8): 691-7 (1997)
2009  
93
Molecular pathways supporting the proliferation staging of malignant melanoma (review).
[19639220] Int J Mol Med 24(3): 295-301 (2009)
1990  
94
CT of malignant melanoma in the chest, abdomen, and musculoskeletal system.
[2198632] Radiographics 10(4): 603-20 (1990)
2007  
95
The role of sentinel lymph node biopsy in the management of melanoma.
[17972569] Adv Surg 41(-): 241-56 (2007)
2011  
96
Angiogenesis and melanoma - from basic science to clinical trials.
[22016833] Am J Cancer Res 1(7): 852-68 (2011)
2011  
97
Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
[22016836] Am J Cancer Res 1(7): 913-24 (2011)
2010  
98
Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
[20555080] Ann Oncol 21 Suppl 5(-): v194-7 (2010)
2010  
99
Advances in systemic treatment of melanoma.
[20943639] Ann Oncol 21 Suppl 7(-): vii339-44 (2010)
2009  
100
Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
[19454433] Ann Oncol 20 Suppl 4(-): 129-31 (2009)
2002  
101
Cellular and molecular biology of human melanoma.
[12170758] Cancer Biol Ther 1(1): 14-7 (2002)
2010  
102
Survival and the sentinel lymph node in melanoma.
[19885700] Ann Surg Oncol 17(1): 18-20 (2010)
2008  
103
Understanding signaling cascades in melanoma.
[18086245] Photochem Photobiol 84(2): 289-306 (2008)
2004  
104
Biological functions of melanoma-associated antigens.
[15222021] World J Gastroenterol 10(13): 1849-53 (2004)
2011  
105
Mayo Clinic consensus recommendations for the depth of excision in primary cutaneous melanoma.
[21628616] Mayo Clin Proc 86(6): 522-8 (2011)
2008  
106
Role of PET in the initial staging of cutaneous malignant melanoma: systematic review.
[19011184] Radiology 249(3): 836-44 (2008)
2010  
107
The biology of melanoma prognostic factors.
[20670603] Discov Med 10(50): 87-93 (2010)
2007  
108
Viewing malignant melanoma cells as macrophage-tumor hybrids.
[19262091] Cell Adh Migr 1(1): 2-6 (2007)
2006  
109
Chemotherapy and targeted therapy combinations in advanced melanoma.
[16609060] Clin Cancer Res 12(7 Pt 2): 2366s-2370s (2006)
2010  
110
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.
[20086001] Clin Cancer Res 16(3): 1042-8 (2010)
2009  
111
Metabolic approaches to treatment of melanoma.
[19861452] Clin Cancer Res 15(21): 6490-4 (2009)
2008  
112
Integrative genomic analysis of aneuploidy in uveal melanoma.
[18172260] Clin Cancer Res 14(1): 115-22 (2008)
2010  
113
Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety.
[20348274] Oncologist 15(4): 416-27 (2010)
2009  
114
What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
[19648604] Oncologist 14(8): 848-61 (2009)
2010  
115
BRAF, a target in melanoma: implications for solid tumor drug development.
[20629085] Cancer 116(21): 4902-13 (2010)
2010  
116
Determinants of survival in patients with brain metastases from cutaneous melanoma.
[20372154] Br J Cancer 102(8): 1213-8 (2010)
2009  
117
Integrating BRAF/MEK inhibitors into combination therapy for melanoma.
[19156138] Br J Cancer 100(3): 431-5 (2009)
2006  
118
Technologies for the diagnosis of primary melanoma of the skin.
[17115962] Med J Aust 185(10): 533-4 (2006)
2005  
119
Clinicopathological features of and risk factors for multiple primary melanomas.
[16204664] JAMA 294(13): 1647-54 (2005)
2010  
120
Ultraviolet a light: potential underlying causes of melanoma.
[21062150] Future Oncol 6(10): 1523-6 (2010)
2008  
121
Emerging insights into the molecular pathogenesis of uveal melanoma.
[18922120] Future Oncol 4(5): 629-36 (2008)
2006  
122
Imaging of metastatic melanoma.
[17208677] Cancer Imaging 6(-): 204-8 (2006)
2009  
123
Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios - part II.
[19556959] Cancer Control 16(3): 196-7 (2009)
2006  
124
Prognosticators of melanoma, the melanoma report, and the sentinel lymph node.
[16446717] Mod Pathol 19 Suppl 2(-): S71-87 (2006)
2006  
125
The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment.
[16446713] Mod Pathol 19 Suppl 2(-): S21-33 (2006)
2003  
126
Grading of atypia in nevi: correlation with melanoma risk.
[12920220] Mod Pathol 16(8): 764-71 (2003)
2011  
127
Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article.
[21552679] Clinics (Sao Paulo) 66(3): 493-9 (2011)
2008  
128
IMP3: a diagnostic and prognostic biomarker in malignant melanoma.
[18785801] Expert Rev Mol Diagn 8(5): 557-8 (2008)
2011  
129
The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth.
[21487158] Oncotarget 2(4): 313-20 (2011)
2011  
130
NUAK2: an emerging acral melanoma oncogene.
[21911917] Oncotarget 2(9): 695-704 (2011)
2011  
131
PLX4032 and melanoma: resistance, expectations and uncertainty.
[21417847] Expert Rev Anticancer Ther 11(3): 325-8 (2011)
2010  
132
Testing the divergent pathway hypothesis for melanoma: recent findings and future challenges.
[20469991] Expert Rev Anticancer Ther 10(5): 615-8 (2010)
2009  
133
Optimizing regional infusion treatment strategies for melanoma of the extremities.
[19895244] Expert Rev Anticancer Ther 9(11): 1599-609 (2009)
2008  
134
Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24.
[18511292] Cytokine 43(1): 34-44 (2008)
2010  
135
IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.
[20216471] Melanoma Res (): (2010)
2006  
136
Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress.
[16908595] Mol Cancer Res 4(8): 575-89 (2006)
2002  
137
The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells.
[11850799] Oncogene 21(5): 708-18 (2002)
2000  
138
Regulation of mda-7 gene expression during human melanoma differentiation.
[10713678] Oncogene 19(10): 1362-8 (2000)
2001  
139
Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas.
[11668478] Int J Cancer 94(1): 54-9 (2001)
2002  
140
Loss of MDA-7 expression with progression of melanoma.
[11844832] J Clin Oncol 20(4): 1069-74 (2002)
2008  
141
Melanoma: what are the gaps in our knowledge.
[18532876] PLoS Med 5(6): e122 (2008)
2007  
142
2005  
143
Perianal melanoma disguised as hemorrhoids: case report and discussion.
[15926652] J Natl Med Assoc 97(5): 726-31 (2005)
2007  
144
Anorectal melanoma. Case report and review of the literature.
[17914500] Rom J Morphol Embryol 48(3): 299-302 (2007)
2005  
145
Melanoma diagnosis by confocal microscopy: promise and pitfalls.
[16193554] J Invest Dermatol 125(3): vii (2005)
2010  
146
Understanding melanoma signaling networks as the basis for molecular targeted therapy.
[19571822] J Invest Dermatol 130(1): 28-37 (2010)
2007  
147
Single-agent interleukin-2 in the treatment of metastatic melanoma.
[17576460] Curr Oncol 14(1): 21-6 (2007)
2007  
148
Temozolomide for the treatment of metastatic melanoma.
[17576461] Curr Oncol 14(1): 27-33 (2007)
2011  
149
Metastatic balloon cell malignant melanoma: a case report and literature review.
[21487528] Int J Clin Exp Pathol 4(3): 315-21 (2011)
2007  
150
Excision margins for primary cutaneous melanoma: updated pooled analysis of randomized controlled trials.
[17875844] Arch Surg 142(9): 885-91; discussion 891-3 (2007)
2003  
151
Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis.
[14680348] Can J Surg 46(6): 419-26 (2003)
2011  
152
FISH as an effective diagnostic tool for the management of challenging melanocytic lesions.
[21834951] Diagn Pathol 6(-): 76 (2011)
2007  
153
Metastatic malignant melanoma in bone marrow with occult primary site--a case report with review of literature.
[17910749] Diagn Pathol 2(-): 38 (2007)
2011  
154
Therapeutic options in cutaneous melanoma: latest developments.
[21957431] Ther Adv Med Oncol 3(5): 245-51 (2011)
2007  
155
Skin diseases with high public health impact. Melanoma.
[17951156] Eur J Dermatol 17(6): 559-62 (2007)
2011  
156
Molecular bases of cutaneous and uveal melanomas.
[21876842] Patholog Res Int 2011(-): 159421 (2011)
2009  
157
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
[19548853] Expert Opin Investig Drugs 18(7): 991-1000 (2009)
2012  
158
RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy.
[22013435] Dermatol Res Pract 2012(-): 354191 (2012)
2012  
159
Smouldering malignant melanoma and metastatic dormancy: an update and review.
[22110487] Dermatol Res Pract 2012(-): 461278 (2012)
2012  
160
miRNAs and Melanoma: How Are They Connected?
[21860617] Dermatol Res Pract 2012(-): 528345 (2012)
2012  
161
Review of diagnostic imaging modalities for the surveillance of melanoma patients.
[21876688] Dermatol Res Pract 2012(-): 941921 (2012)
2010  
162
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
[21074063] Semin Oncol 37(5): 473-84 (2010)
2007  
163
2009  
164
Melanoma in pediatric, adolescent, and young adult patients.
[19835737] Semin Oncol 36(5): 419-31 (2009)
2010  
165
Mouse models for melanoma: a personal perspective.
[19849715] Exp Dermatol 19(2): 157-64 (2010)
2010  
166
The role of ultraviolet radiation in melanomagenesis.
[20067521] Exp Dermatol 19(2): 81-8 (2010)
2010  
167
Sox proteins in melanocyte development and melanoma.
[20444197] Pigment Cell Melanoma Res 23(4): 496-513 (2010)
2010  
168
Roles of endothelin signaling in melanocyte development and melanoma.
[20128875] Pigment Cell Melanoma Res 23(2): 160-70 (2010)
2010  
169
2009  
170
Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt.
[19708915] Pigment Cell Melanoma Res 22(6): 724-39 (2009)
2009  
171
Treatment of metastatic melanoma: an overview.
[19544689] Oncology (Williston Park) 23(6): 488-96 (2009)
2010  
172
Progress in understanding melanoma propagation.
[20655286] Mol Oncol 4(5): 451-7 (2010)
2010  
173
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
[20630094] J Transl Med 8(-): 67 (2010)
2011  
174
Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior.
[21949569] World J Biol Chem 2(9): 193-201 (2011)
2010  
175
Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.
[20459375] Curr Mol Med 10(4): 405-12 (2010)
2011  
176
Autotaxin: its role in biology of melanoma cells and as a pharmacological target.
[21423677] Enzyme Res 2011(-): 194857 (2011)
2010  
177
Melanocytes in development and cancer.
[19795394] J Cell Physiol 222(1): 38-41 (2010)
2009  
178
Targeted therapy in melanoma.
[20054438] Biologics 3(-): 475-84 (2009)
2009  
179
Long-term pegylated interferon-alpha and its potential in the treatment of melanoma.
[19707406] Biologics 3(-): 169-82 (2009)
2011  
180
Insulin-like growth factor system and sporadic malignant melanoma.
[21224039] Am J Pathol 178(1): 26-31 (2011)
2011  
181
Targeting BRAF for patients with melanoma.
[21139585] Br J Cancer 104(3): 392-8 (2011)
2010  
182
Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.
[21204754] Cancer Biother Radiopharm 25(6): 601-13 (2010)
2010  
183
Malignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins.
[20936327] Cancer Metastasis Rev 29(4): 777-84 (2010)
2010  
184
Pure desmoplastic melanoma: a melanoma with distinctive clinical behavior.
[21107116] Ann Surg 252(6): 1052-7 (2010)
2010  
185
Histologically ambiguous ("borderline") primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy.
[21128774] Arch Pathol Lab Med 134(12): 1770-7 (2010)
2010  
186
Sentinel lymph nodes in cutaneous melanoma: handling, examination, and clinical repercussion.
[21128773] Arch Pathol Lab Med 134(12): 1764-9 (2010)
2010  
187
Prognostication in thin cutaneous melanomas.
[21128772] Arch Pathol Lab Med 134(12): 1758-63 (2010)
2010  
188
Cellular heterogeneity in vertical growth phase melanoma.
[21128771] Arch Pathol Lab Med 134(12): 1750-7 (2010)
2010  
189
Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.
[21128770] Arch Pathol Lab Med 134(12): 1740-9 (2010)
2010  
190
Malignant melanoma (metastatic).
[21418691] Clin Evid (Online) 2010(): (2010)
2011  
191
Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases.
[21151100] Mod Pathol 24(5): 613-23 (2011)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


  • Malignes Melanom: Diagnostik, Therapie und Nachsorge


  • Search PubMed and many other databases on the combined search terms

    GG: melanoma

  • Haut (Neubildung Melanom)

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia